Chemed Corporation (NYSE: CHE) raised its full-year 2026 adjusted diluted earnings per share (EPS) guidance to a range of $25.00 to $25.75, surpassing the $24.34 analyst estimate. The upward revision follows second-quarter results that showed a 43.7% year-over-year increase in GAAP diluted EPS to $5.13, driven by robust performance in its VITAS Healthcare segment and a significant reduction in Medicare Cap billing limitations.

The updated outlook reflects management’s confidence in returning VITAS to normal growth patterns after navigating regulatory constraints in 2025. The midpoint of the revised guidance represents a 17.8% increase over the 2025 adjusted EPS of $21.55. This improvement is underpinned by higher expected patient volume growth and expanded margin profiles, positioning the company to outperform market expectations for the fiscal year.

Q2 Performance Drivers

Consolidated revenue rose 8.8% to $673.3 million, while adjusted diluted EPS climbed 41.9% to $6.06. VITAS Healthcare was the primary catalyst, with net patient revenue surging 11.9% to $443.3 million. This growth was fueled by a 6.1% increase in average daily census (ADC) and a 9.0% rise in admissions. Crucially, VITAS accrued only $500,000 in Medicare Cap billing limitations in the quarter, a dramatic improvement from the $16.4 million recorded in the same period last year. Consequently, VITAS’ adjusted EBITDA, excluding Medicare Cap, jumped 20.6% to $80.6 million, with margins expanding by 196 basis points to 18.2%.

In contrast, the Roto-Rooter segment showed muted profitability. Revenue increased modestly by 3.3% to $229.9 million, but adjusted EBITDA remained essentially flat at $48.5 million. The segment’s adjusted EBITDA margin contracted by 77 basis points to 21.1%, pressured by higher selling, general, and administrative expenses that rose 11.3% year-over-year. Commercial branch revenue grew 6.8%, outpacing residential revenue growth of 1.7%, indicating a shift in demand toward commercial plumbing services.

Revised Full-Year Guidance

Management revised its full-year 2026 guidance upward across key metrics. The table below outlines the changes from the previous Q1 release:

Roto-Rooter’s full-year guidance remains unchanged, with anticipated revenue growth of 3.0% to 3.5% and an estimated adjusted EBITDA margin of 21.5% to 22.5%.

What the Numbers Show

The divergence between VITAS and Roto-Rooter highlights Chemed’s shifting operational dynamics. While Roto-Rooter faces margin compression due to rising SG&A costs despite top-line growth, VITAS is demonstrating strong leverage from volume increases. The drastic reduction in Medicare Cap accruals—from $16.4 million to just $500,000—suggests that VITAS has successfully navigated regulatory constraints, allowing nearly all incremental patient days to translate directly into revenue and EBITDA growth. This structural improvement in VITAS is the primary driver behind the consolidated EPS surge, overshadowing the stagnant profitability in the plumbing services division.

Activist investor Barington Capital Group is urging Chemed to conduct a comprehensive strategic review of its operations. The firm has also demanded the implementation of immediate cost cuts to enhance shareholder value. This intervention highlights growing pressure on the company to optimize its business structure and financial performance.

Barington's proposal focuses on evaluating Chemed's current business segments to identify potential areas for improvement or divestment. The activist firm believes that a thorough review will uncover opportunities to streamline operations and drive profitability. The call for cost reductions targets operational inefficiencies that may be weighing on the company's margins.

The involvement of Barington Capital Group signals a significant shift in the narrative surrounding Chemed's management strategy. Shareholders are likely to monitor the company's response closely, as the outcome of this engagement could influence future stock performance. Chemed has not yet issued a public statement regarding the activist's demands.

Key Demands by Barington Capital Group

The situation remains fluid as stakeholders await further developments from both Chemed and Barington Capital Group.